醫思健康(02138.HK)上半財年銷售額按年增長逾60%
醫思健康(02138.HK)公布,截至今年9月底止六個月整體銷售額逾15.2億元,按年增長不少於60%,較2019年同期增長逾43%。其中內地銷售額按年增長逾34%,較2019年同期增長至少94%;醫療服務銷售額按年增長超過一倍,較2019年同期增長至少1.52倍。
公司認為,增長主要是由於隨著本港新型肺炎疫苗接種率上升,對公司提供的醫療服務有強勁需求。另外,隨著疫情受控,及港府推出消費券計劃,本地消費情緒改善及零售業全面復甦。上一財政年度下半年收購醫療資產亦產生正面協同效應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.